Connor, Clark & Lunn Investment Management (CC&L)’s Terns Pharmaceuticals TERN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.3M	Buy	384,681 +247,203	+180%	+$10.2M	0.05%	312
2025 Q4	$5.55M	Buy	+137,478	New	+$3.18M	0.01%	617
2025 Q1	–	Sell	-74,858	Closed	-$415K	–	1597
2024 Q4	$415K	Buy	74,858 +21,845	+41%	+$148K	﹤0.01%	1190
2024 Q3	$442K	Buy	+53,013	New	+$436K	﹤0.01%	1126
2023 Q4	–	Sell	-67,957	Closed	-$342K	–	1555
2023 Q3	$342K	Sell	67,957 -4,230	-6%	-$26.8K	﹤0.01%	1116
2023 Q2	$632K	Buy	72,187 +60,224	+503%	+$702K	﹤0.01%	927
2023 Q1	$142K	Buy	+11,963	New	+$114K	﹤0.01%	1129

Other funds holding TERN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TERN Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Terns Pharmaceuticals (TERN) stake by 180% in Q1 2026, buying an estimated $10.2M and bringing the position to 384,681 shares worth $20.3M. The position accounts for 0.05% of the portfolio, ranked #312.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TERN in Q1 2023 and has held it in 7 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 384,681 shares of Terns Pharmaceuticals worth $20.3M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 247,203 Terns Pharmaceuticals shares in Q1 2026, an estimated $10.2M.
Terns Pharmaceuticals made up 0.05% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #312 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.